RFA-DK-22-509: Limited Competition for the Continuation of the NIDDK Diabetic Foot Consortium - Clinical Research Units (U01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $365,000 to small businesses. Applications closed on August 17, 2022.
From the official notice on Grants.gov, last changed June 7, 2022. Checked November 7, 2026.
- Award ceiling$365,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsOptional
- Funded byNIDDK
- Median yearly award$727,080
- Typical project length9.5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-DK-22-509 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-22-509 in the NIH Guide.
Key dates
| Posted | June 7, 2022 |
|---|---|
| Deadline | August 17, 2022 |
| Archived by Grants.gov | September 22, 2022 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See Full Announcement for additional eligibility information
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $727,080; it allows up to $365,000 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The Diabetic Foot Consortium (DFC) is the first clinical network for the study of diabetic foot ulcers (DFUs) a common, expensive, and debilitating complication of diabetes that leads to over 100,000 amputations in the United States every year. The DFC was started to address this significant public health problem by building a research infrastructure and validating biomarkers to predict healing or recurrence of DFUs. This Limited Competition Funding Opportunity Announcement (FOA) calls for the renewal of the Clinical Research Units (CRUs) for their support of an expansion of the mission of the DFC with the following goals: 1) develop and validate biomarkers for DFUs;2) accelerate advances in DFU standard care; 3) characterize the role of social determinants of health for DFU healing and recurrence; and 4) build on the DFC infrastructure through ancillary studies and satellite sites. Future research may involve clinical trials and studies on the pathophysiology and prevention of DFUs. All protocol interactions in the DFC will occur at the CRUs. They will recruit participants, collect longitudinal data, images and biosamples and send these data and biosamples to the Data Coordinating Center and Biomarker Analysis Units. They will also collaborate with Satellite sites to accelerate the pace of the DFC studies. As members of the Steering Committee, they will provide leadership in developing protocols and setting priorities for the DFC to best leverage its resources to improve clinical research and care for DFUs.
Funded under RFA-DK-22-509 so far
NIH funded 4 projects under RFA-DK-22-509 in fiscal 2023 to 2026, at 4 institutions. The median yearly award was $727,080.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| UCSF Diabetic Foot Clinical Research Unit | University of California, San Francisco | 2026 | $780,048 |
| The University of Arizona Wound Care Center Clinical Research Unit | University of Arizona | 2026 | $44,513 |
| Diabetic Foot Consortium Clinical Research Unit | University of Pittsburgh at Pittsburgh | 2026 | $758,276 |
| NIDDK Diabetic Foot Consortium Clinical Research Unit | University of Michigan at Ann Arbor | 2026 | $727,080 |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-22-509 still open?
No. It closed on August 17, 2022.
Who can apply for Limited Competition for the Continuation of the NIDDK Diabetic Foot Consortium - Clinical Research Units (U01 Clinical Trial Optional)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition for the Continuation of the NIDDK Diabetic Foot Consortium - Clinical Research Units (U01 Clinical Trial Optional)?
Closed August 17, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $365,000 each.
Who has been funded under RFA-DK-22-509?
NIH RePORTER lists 4 projects funded under RFA-DK-22-509 in fiscal 2023 to 2026, at 4 institutions. The most were at University of California, San Francisco, University of Arizona, University of Pittsburgh at Pittsburgh.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)
- Neural Ensembles & Used Substances (NExUS) Collaboratory: Building a Multimodal Inventory of Cell Ensembles Encoding the Effects of Addictive Substances (U01 Clinical Trial Not Allowed)
- Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)